Journal Browser

► Journal Browser

Special Issue Editors

E-Mail Website
Guest Editor

School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, Australia
Interests: peptide-based vaccines; peptide synthesis; synthesis of enzyme inhibitors; gene delivery; peptide conjugations; drug design; group A streptococcus; malaria; human papilloma virus; mycobacterium tuberculosis
Special Issues, Collections and Topics in MDPI journals

Dr. Rachel Stephenson

E-Mail Website
Guest Editor

School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia
Interests: group A streptococcus glycoconjuagte vaccines; cyclic peptides as vaccine delivery platforms; peptide delivery systems; subunit vaccine development

Dr. Mariusz Skwarczynski

E-Mail Website
Guest Editor

School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
Interests: nanotechnology; peptide chemistry; medicinal chemistry; vaccine/drug delivery; antimicrobial agents; prodrug strategies; macromolecules; adjuvants
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vaccination is one of the most successful tools for reducing the incidence of infectious diseases. Peptide-based subunit vaccines have emerged as promising prophylactic and therapeutic medication against several infectious diseases including group A streptococcus, malaria, TB, and cancer. Peptide-subunit-based vaccines contain only the minimal immunogenic region of an antigen necessary to elicit the desired immune response. Therefore, only safe and effective epitopes can be selected, removing the risk of allergic and autoimmune responses. However, peptides do not contain the danger signals that are needed to activate the immune system. Thus, an adjuvant/delivery system must be included to stimulate an immune response against the peptide antigen.

Dr. Waleed Hussein
Dr. Rachel Stephenson
Dr. Mariusz Skwarczynski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

peptide-based vaccine
infectious Diseases
prophylactic vaccines
therapeutic vaccines
cancer
vaccine formulations
adjuvants

Published Papers (2 papers)

Download All Papers

Review

Open AccessFeature PaperReview

Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic Targets as a New Approach for Breast Cancer: A Review

María Lilia Nicolás-Morales

Arianna Luisa-Sanjuan

Mayralina Gutiérrez-Torres

Amalia Vences-Velázquez

Carlos Ortuño-Pineda

Mónica Espinoza-Rojo

Napoleón Navarro-Tito

and

Karen Cortés-Sarabia

Vaccines 2022, 10(8), 1249; https://doi.org/10.3390/vaccines10081249 - 03 Aug 2022

Cited by 3 | Viewed by 1693

Abstract

Breast cancer is the leading cause of death in women from 20 to 59 years old. The conventional treatment includes surgery, chemotherapy, hormonal therapy, and immunotherapy. This immunotherapy is based on administering monoclonal therapeutic antibodies (passive) or vaccines (active) with therapeutic purposes. Several types of vaccines could be used as potential treatments for cancer, including whole-cell, DNA, RNA, and peptide-based vaccines. Peptides used to develop vaccines are derived from tumor-associated antigens or tumor-specific antigens, such as HER-2, MUC1, ErbB2, CEA, FRα, MAGE A1, A3, and A10, NY-ESO-1, among others. Peptide-based vaccines provide some advantages, such as low cost, purity of the antigen, and the induction of humoral and cellular immune response. In this review, we explore the different types of vaccines against breast cancer with a specific focus on the description of peptide-based vaccines, their composition, immune response induction, and the description of new potential therapeutic targets. Full article

(This article belongs to the Special Issue Peptide-Based Vaccines against Infectious Diseases and Cancer)

► Show Figures

Figure 1

Open AccessReview

Advances in Infectious Disease Vaccine Adjuvants

and

Vaccines 2022, 10(7), 1120; https://doi.org/10.3390/vaccines10071120 - 13 Jul 2022

Cited by 9 | Viewed by 3275

Abstract

Vaccines are one of the most significant medical interventions in the fight against infectious diseases. Since their discovery by Edward Jenner in 1796, vaccines have reduced the worldwide transmission to eradication levels of infectious diseases, including smallpox, diphtheria, hepatitis, malaria, and influenza. However, the complexity of developing safe and effective vaccines remains a barrier for combating many more infectious diseases. Immune stimulants (or adjuvants) are an indispensable factor in vaccine development, especially for inactivated and subunit-based vaccines due to their decreased immunogenicity compared to whole pathogen vaccines. Adjuvants are widely diverse in structure; however, their overall function in vaccine constructs is the same: to enhance and/or prolong an immunological response. The potential for adverse effects as a result of adjuvant use, though, must be acknowledged and carefully managed. Understanding the specific mechanisms of adjuvant efficacy and safety is a key prerequisite for adjuvant use in vaccination. Therefore, rigorous pre-clinical and clinical research into adjuvant development is essential. Overall, the incorporation of adjuvants allows for greater opportunities in advancing vaccine development and the importance of immune stimulants drives the emergence of novel and more effective adjuvants. This article highlights recent advances in vaccine adjuvant development and provides detailed data from pre-clinical and clinical studies specific to infectious diseases. Future perspectives into vaccine adjuvant development are also highlighted. Full article

(This article belongs to the Special Issue Peptide-Based Vaccines against Infectious Diseases and Cancer)

► Show Figures

Graphical abstract

Journal Menu

Journal Browser

Special Issue "Peptide-Based Vaccines against Infectious Diseases and Cancer"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (2 papers)

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI